Intervention

Moxifloxacin

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 36 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials36
Recruiting0
Common conditions25
Lead sponsors shown15
Advertisement

Clinical trials

36 shown
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)NCT07595042 · 2026-10-30
NOT_YET_RECRUITING
Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157 · 2025-10-22
COMPLETED
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityNCT06200467 · 2024-03-13
COMPLETED
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)NCT05893862 · 2023-06-26
COMPLETED
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsNCT05804162 · 2023-04-12
COMPLETED
Thorough QT Study to Evaluate Ampreloxetine in Healthy SubjectsNCT04688632 · 2021-01-18
COMPLETED
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of MoxifloxacinNCT04563845 · 2020-11-09
COMPLETED
A Through QT/QTc Study of KW-6356NCT04342273 · 2020-03-31
COMPLETED
Effect of Glucose on QTc Interval in Type 1 DiabetesNCT01984827 · 2019-02-10
COMPLETED
Phase I Study of OPC-61815NCT03510663 · 2018-05-08
COMPLETED
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" EpisodesNCT03187301 · 2017-08-03
COMPLETED
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy VolunteersNCT04019652 · 2015-11-19
COMPLETED
Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsNCT02164812 · 2014-07-01
COMPLETED
AZD3293 Thorough QT Study in Healthy Male VolunteersNCT02040987 · 2014-01-01
COMPLETED
Study to Evaluate the Effect of GSK1265744 on Cardiac ConductionNCT02027454 · 2014-01-01
COMPLETED
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mgNCT01658020 · 2012-08-01
COMPLETED
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With SchizophreniaNCT01606436 · 2012-06-01
COMPLETED
QTc Study GSK573719+GW642444NCT01521377 · 2011-12-19
COMPLETED
Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)NCT01398072 · 2011-12-01
UNKNOWN
A Study on the Effects of LY2409021 on the Electrical Impulses of the HeartNCT01460368 · 2011-10-01
COMPLETED
Albiglutide Thorough ECG Study in Healthy VolunteersNCT01406262 · 2011-07-06
COMPLETED
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective DisorderNCT01423916 · 2011-07-01
COMPLETED
Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the HeartNCT01359618 · 2011-06-01
TERMINATED
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy SubjectsNCT01297062 · 2011-02-01
COMPLETED
To Evaluate the Effect of AZD3199 on the Electrical Activity in the HeartNCT01222442 · 2010-11-01
COMPLETED
Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and EfficacyNCT01091493 · 2010-07-01
COMPLETED
The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy SubjectsNCT00936871 · 2010-01-01
COMPLETED
Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsNCT00979316 · 2009-09-01
COMPLETED
QTc Study of Rosi XR in Healthy VolunteersNCT00884533 · 2009-06-01
WITHDRAWN
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the HeartNCT00887770 · 2009-04-01
COMPLETED
Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy VolunteersNCT00777595 · 2008-10-01
COMPLETED
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)NCT00708903 · 2008-05-01
COMPLETED
Study Evaluating the Effect of Lecozotan SR on the QTc IntervalNCT00499642 · 2007-06-01
COMPLETED
Moxifloxacin As Part of a Multi-Drug Regimen For TuberculosisNCT00082173 · 2004-10-01
COMPLETED
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary TuberculosisNCT00396084 · 2004-02-10
COMPLETED
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or PlaceboNCT00158093 · 2003-06-01
COMPLETED

Common conditions

Chronic Obstructive Pulmonary Disease4Obesity3Tuberculosis3Alzheimer Disease2Alzheimer's Disease2Diabetes Mellitus, Type 22Hypertension2Overweight2Parkinson's Disease2Schizophrenia2Breast Cancer1Chronic Obstructive Pulmonary Disease (COPD).1Congestive Heart Failure1Diabetes1Healthy1Healthy Male1Healthy Subjects1Healthy Volunteers1HIV Infections1HIV/AIDS1Infection, Human Immunodeficiency Virus1Lung Disease1Mineralocorticoid Receptor Antagonist1nOH1Off Episodes of Parkinson Disease1

Trial status mix

COMPLETED32
NOT_YET_RECRUITING1
TERMINATED1
UNKNOWN1
WITHDRAWN1

Phase mix

PHASE130
PHASE24
PHASE32
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.